glp-1 drugs impact on energy levels How Weight-Loss Affect Appetite, Mood, and Behavior Consumers' Expectations about GLP-1 Drugs
Description
Identical Pharmacy eligibility criteria to SGLT-2 inhibitor Empagliflozin, but funding is either or Some patient could benefit from both SGLT-2 inhibitor and GLP-1 agonists

Cardiovascular and hemodynamic effects of glucagon-like peptide-1
doi: 10.1016/j.brainres.2012.07.029 168 ParthsarathyVHolscherC

108 In March 2015, the FDA required a black box warning on Tanzeum due to the observed risk of thyroid C-cell tumors in animals, although it is unclear if this effect also occurs in humans

The weight loss ranges of the two treatment groups were -6.9 kg (-7%) and -9.7 kg (-9.6%), respectively

Mounjaro (tirzepatide) uniquely targets both GLP-1 and GIP receptors, potentially offering more substantial weight reduction and improved glycemic control compared to other GLP-1RAs that only target the GLP-1 receptor, such as Ozempic (semaglutide)
